Aquinox Pharmaceuticals brings in second corporate venturing unit to bolster its $25m series B round.
US-listed drugs company Pfizer’s corporate venturing unit has joined healthcare peer Johnson & Johnson’s equivalent as a strategic investor in Aquinox Pharmaceuticals’ $25m funding round.
Aquinox, a Canada-based drug company focused on cancer and inflammatory disease, raise the $25m in its series B round. Venture capital firm Ventures West Capital led the round, and was joined by fellow return backers Johnson & Johnson Development Corporation (JJDC), Baker Brothers Investments and BC Advantage Funds with Pfizer Venture Investments as a new…
